Performance over 1-Year: 225.8% Expense Ratio: 0.75% Annual Dividend Yield: 0.73% 3-Month Average Daily Volume: 4,543,848 Assets Under Management: $11.6 billion Inception Date: October 31, 2014 Issuer: ARK Investment Management
An actively-managed multi-cap fund, ARKG seeks to add value by identifying companies most likely to profit from the latest scientific advances. Examples of areas in which the company has invested include stem cell research, gene editing, genetic therapy, and molecular diagnostics. The fund is largely focused on growth stocks in the U.S. biotechnology sector, and its three largest holdings are Teladoc Health Inc. (TDOC), a telemedicine and virtual health company; Pacific Biosciences of California Inc. (PACB), a designer and manufacturer of genetic sequencing technologies; and Twist Bioscience Corp. (TWST), a company that manufactures synthetic DNA for the biotechnology industry.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.